Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00422812 · ClinicalTrials.gov registry record · Phase 2
Staccato Prochlorperazine in Migraine (Out Patient)
A Phase 2 study, sponsored by Alexza Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 400
- Enrollment target
NCT00422812: Completed Phase 2 study, sponsored by Alexza Pharmaceuticals.
NCT00422812 is a Phase 2 study that has completed, run by Alexza Pharmaceuticals. The registered enrollment target is 400 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (201% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00422812, a Phase 2 study, has completed, sponsored by Alexza Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 400 participants
- Enrollment target
Study Summary
Staccato Prochlorperazine is being developed to treat patients suffering from acute migraine headaches. In October 2005, we completed a 75 patient, multi-center, double-blind placebo-controlled Phase 2A clinical trial in patients suffering from moderate to severe acute migraine headaches. This Phase 2B clinical trial of Staccato Prochlorperazine has been initiated to assess the efficacy and safety in outpatients with migraine headache with or without aura.
Primary Outcome
Headache pain relief at 2 hr post-dose by IHS Definition (none=0 or mild=1),
Interventions
- DRUG Inhaled Placebo
- DRUG Inhaled PCZ 5 mg
- DRUG Inhaled PCZ 7.5 mg
- DRUG Inhaled PCZ 10 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2006-04 |
| Est. Completion | 2007-01 |
| Phase | Phase 2 |
What the finished NCT00422812 record still lists
NCT00422812 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (201% higher).
The record links to 0 conditions, and to 4 interventions - of which Inhaled Placebo is the first listed.
NCT00422812 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00422812 about?
NCT00422812 is a clinical study titled "Staccato Prochlorperazine in Migraine (Out Patient)". Staccato Prochlorperazine is being developed to treat patients suffering from acute migraine headaches. In October 2005, we completed a 75 patient, multi-center, double-blind placebo-controlled Phase 2A clinical trial in patients suffering from moderate to severe acute migraine headaches. This Phase...
What is the current status of trial NCT00422812?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 400 participants. The study started on 2006-04. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00422812?
The interventions under investigation include: Inhaled Placebo (DRUG), Inhaled PCZ 5 mg (DRUG), Inhaled PCZ 7.5 mg (DRUG), Inhaled PCZ 10 mg (DRUG).
Who is sponsoring clinical trial NCT00422812?
This trial is sponsored by Alexza Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00422812's enrollment target sits among peer trials
400 96th of 2000 higher than 1,898 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia